Biotage AB (BIOT) AI Stock Analysis

• Market Cap: $11.40B
• Dividend Yield: 1.04%
• Average Volume (3M): 874.23K
• Price to Earnings (P/E): 44.5
• Beta (1Y): 1.05
• Revenue Growth: -1.01%
• EPS Growth: 6.10%
• Country: SE
• Employees: 622
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 3.20
• Shares Outstanding: 80,049,270
• 10 Day Avg. Volume: 660,773
• 30 Day Avg. Volume: 874,226
• PEG Ratio: -4.35
• Price to Book (P/B): 2.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 59.19
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $143.02
• Price Target Upside: 0.44% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 72 Outperform
• Price Target: ―

Biotage AB demonstrates strong financial performance with solid profitability and balance sheet stability. However, the technical analysis suggests caution due to potential overbought conditions and mixed price trends. The valuation appears high, which might limit upside potential despite a reasonable dividend yield. Overall, the company is fundamentally strong, but market conditions and valuation demand careful consideration.

Biotage AB Business Overview & Revenue Model

Company Description

Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems and flash system accessories; normal, reversed, and speciality phase cartridges; plasmid purification solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and government authorities and academic institutions, as well as clinical, forensic, and academic laboratories. It operates in 70 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.

How the Company Makes Money

Biotage AB generates revenue primarily through the sale of its scientific instruments and consumables. The company offers a comprehensive range of products that are integral to laboratory workflows, including systems for separation and purification, as well as sample preparation products. These products are sold directly to laboratories and research institutions worldwide. In addition to product sales, Biotage generates income through service contracts and support agreements, which provide ongoing maintenance and technical assistance to its customers. The company also benefits from strategic partnerships and collaborations with other firms in the life sciences sector, which can lead to joint development projects and expanded market reach.

Biotage AB Financial Statement Overview

Summary

Biotage AB presents a strong financial profile with robust revenue growth, profitability, and balance sheet stability. The company effectively manages its debt, maintaining low leverage while generating consistent earnings and cash flow. Despite some fluctuations in growth rates and margins, Biotage AB remains well-positioned within the Medical - Instruments & Supplies industry.

Income Statement

Biotage AB has demonstrated strong financial performance with consistent growth in revenues and net income over the years. The company maintains a healthy gross profit margin of 62.7% for TTM, indicating efficient cost management. However, the net profit margin for TTM has slightly decreased to 13.1% from the previous annual figure of 13.8%. The revenue growth rate shows a slight decline of 4.6% from 2024 to TTM, but overall, the company's income statement reflects robust profitability and growth.

Balance Sheet

The balance sheet of Biotage AB is solid with a strong equity base, reflected in an equity ratio of 81.7% for TTM. The company has effectively managed its debt levels, with a low debt-to-equity ratio of 0.06. Return on equity stands at 6.7% for TTM, indicating moderate efficiency in generating returns for shareholders. Overall, the balance sheet showcases financial stability with low leverage and high shareholder equity.

Cash Flow

Biotage AB's cash flow statement indicates healthy cash generation capabilities, with a free cash flow of 188 million for TTM. However, the free cash flow has decreased by 22.9% compared to the previous year. The operating cash flow to net income ratio of 1.36 for TTM suggests efficient cash conversion from net income. Despite a decline in free cash flow, the company maintains a strong operating cash flow, reflecting good liquidity and cash management.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.96B	2.06B	1.86B	1.57B	1.23B	1.09B
	Gross Profit
1.23B	1.29B	1.01B	948.00M	755.00M	666.73M
	EBIT
312.00M	383.00M	376.00M	327.00M	271.00M	206.19M
	EBITDA
491.00M	568.00M	432.00M	431.00M	323.00M	278.10M
	Net Income Common Stockholders
256.00M	284.00M	246.00M	268.00M	205.00M	175.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
420.00M	434.00M	594.00M	441.00M	311.00M	371.32M
	Total Assets
4.71B	5.10B	4.93B	2.34B	1.99B	1.43B
	Total Debt
238.00M	250.00M	259.00M	217.00M	203.00M	212.69M
	Net Debt
-182.00M	-184.00M	-335.00M	-224.00M	-108.00M	-158.63M
	Total Liabilities
862.00M	991.00M	1.27B	702.00M	620.00M	444.40M
	Stockholders Equity
3.85B	4.11B	3.66B	1.64B	1.37B	990.04M
Cash Flow		Free Cash Flow
188.00M	244.00M	258.00M	271.00M	297.00M	218.11M
	Operating Cash Flow
348.00M	413.00M	284.00M	341.00M	353.00M	279.05M
	Investing Cash Flow
-437.00M	-456.00M	35.00M	-84.00M	-341.00M	-61.32M
	Financing Cash Flow
-158.00M	-156.00M	-142.00M	-133.00M	-82.00M	-22.72M

Biotage AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 142.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOT, the sentiment is Positive. The current price of 142.4 is above the 20-day moving average (MA) of 141.82, above the 50-day MA of 122.69, and below the 200-day MA of 145.80, indicating a neutral trend. The MACD of 4.21 indicates Positive momentum. The RSI at 77.00 is Negative, neither overbought nor oversold. The STOCH value of 64.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOT.

Biotage AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOT	72 Outperform	$11.40B	44.52	6.41%	1.04%	-1.01%	6.10%
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
ADDLF		$2.43B	84.72	5.83%	0.35%	―	―
BOEUF		$1.83B	159.43	18.01%	―	―	―
RSLBF		$1.17B	55.66	25.53%	0.82%	―	―
XVIPF		$1.04B	80.04	6.57%	―	―	―
SUS		kr7.75B	54.90		―	―	―

Biotage AB Corporate Events

Biotage AB Increases Voting Rights Through Share Reclassification

Biotage AB has re-classified 2,611 class C shares to ordinary shares as part of its long-term incentive plan from 2022. This re-classification has increased the total number of votes in the company by 2,349.9, while the total number of shares remains unchanged, reflecting a strategic move to fulfill commitments to participants in the incentive plan.